FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225793605> ?p ?o ?g. }

• W4225793605 abstract "Patent foramen ovale (PFO) is the most common congenital heart defect with an estimated prevalence of 1 in 4 adults. The optimal treatment strategy for patients with PFO with cryptogenic stroke has long been debated. Early clinical trials, including Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment (RESPECT) (NCT00465270), Patent Foramen Ovale and Cryptogenic Embolism (PC) (NCT00166257), and Evaluation of the STARFlex Septal Closure System in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale (CLOSER) I (NCT00201461), did not show benefit for PFO closure in the reduction of recurrent embolic stroke and/or systemic embolism compared with medical therapy. More recent trials, including Device Closure Versus Medical Therapy for Cryptogenic Stroke Patients With High-Risk Patent Foramen Ovale (DEFENSE-PFO) (NCT01550588), GORE® Septal Occluder Device for Patent Foramen Ovale (PFO) Closure in Stroke Patients (REDUCE) (NCT00738894), and Patent Foramen Ovale Closure or Anticoagulants Versus Antiplatelet Therapy to Prevent Stroke Recurrence (CLOSE) (NCT00562289) trials and the 10-year results of the RESPECT trial, demonstrated that PFO closure with a variety of devices in combination with medical management reduced recurrent stroke and/or systemic embolism compared with medical therapy alone. Given these new findings, society guidelines have been updated to reflect improved outcomes with device closure of PFO in patients 60 years or younger with a PFO-related stroke diagnosed by a neurologist with vascular expertise. 1 Messé SR Gronseth GS Kent DM Kizer JR Homma S Rosterman L Carroll JD Ishida K Sangha N Kasner SE. Practice advisory update summary: patent foramen ovale and secondary stroke prevention: report of the Guideline Subcommittee of the American Academy of Neurology. Neurology. 2020; 94: 876-885 Crossref PubMed Scopus (57) Google Scholar ,2 Pristipino C Sievert H D'Ascenzo F Mas JL Meier B Scacciatella P Hildick-Smith D Gaita F Toni D Kyrle P Thomson J Derumeaux G Onorato E Sibbing D Germonpré P Berti S Chessa M Bedogni F Dudek D Hornung M Zamorano J European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Stroke Organisation (ESO), European Heart Rhythm Association (EHRA), European Association for Cardiovascular Imaging (EACVI), Association for European Paediatric and Congenital Cardiology (AEPC), ESC Working group on GUCH, ESC Working group on Thrombosis, European Haematological Society (EHA)European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism. EuroIntervention. 2019; 14: 1389-1402 Crossref PubMed Scopus (68) Google Scholar Based on this subsequent favorable data, the Food and Drug Administration has approved PFO for cryptogenic stroke in patients 60 years or younger. However, given the differences in outcomes of these trials, the optimal treatment strategy in patients with PFO (percutaneous closure vs medical therapy) remains controversial." @default.
• W4225793605 created "2022-05-05" @default.
• W4225793605 creator A5006567146 @default.
• W4225793605 creator A5026578587 @default.
• W4225793605 creator A5044514674 @default.
• W4225793605 creator A5050686676 @default.
• W4225793605 creator A5054589840 @default.
• W4225793605 creator A5065058975 @default.
• W4225793605 creator A5071042848 @default.
• W4225793605 creator A5076413230 @default.
• W4225793605 creator A5079469441 @default.
• W4225793605 date "2022-04-01" @default.
• W4225793605 modified "2023-09-28" @default.
• W4225793605 title "Meta-Analysis Comparing Percutaneous Closure Versus Medical Therapy for Patent Foramen Ovale" @default.
• W4225793605 cites W2805884725 @default.
• W4225793605 cites W2890250284 @default.
• W4225793605 cites W3021667850 @default.
• W4225793605 cites W4240033568 @default.
• W4225793605 doi "https://doi.org/10.1016/j.amjcard.2022.03.013" @default.
• W4225793605 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35393082" @default.
• W4225793605 hasPublicationYear "2022" @default.
• W4225793605 type Work @default.
• W4225793605 citedByCount "0" @default.
• W4225793605 crossrefType "journal-article" @default.
• W4225793605 hasAuthorship W4225793605A5006567146 @default.
• W4225793605 hasAuthorship W4225793605A5026578587 @default.
• W4225793605 hasAuthorship W4225793605A5044514674 @default.
• W4225793605 hasAuthorship W4225793605A5050686676 @default.
• W4225793605 hasAuthorship W4225793605A5054589840 @default.
• W4225793605 hasAuthorship W4225793605A5065058975 @default.
• W4225793605 hasAuthorship W4225793605A5071042848 @default.
• W4225793605 hasAuthorship W4225793605A5076413230 @default.
• W4225793605 hasAuthorship W4225793605A5079469441 @default.
• W4225793605 hasConcept C126322002 @default.
• W4225793605 hasConcept C127413603 @default.
• W4225793605 hasConcept C141071460 @default.
• W4225793605 hasConcept C146834321 @default.
• W4225793605 hasConcept C162324750 @default.
• W4225793605 hasConcept C164705383 @default.
• W4225793605 hasConcept C168563851 @default.
• W4225793605 hasConcept C2776893843 @default.
• W4225793605 hasConcept C2777185221 @default.
• W4225793605 hasConcept C2779695227 @default.
• W4225793605 hasConcept C2779987240 @default.
• W4225793605 hasConcept C2780645631 @default.
• W4225793605 hasConcept C2780813298 @default.
• W4225793605 hasConcept C34447519 @default.
• W4225793605 hasConcept C71924100 @default.
• W4225793605 hasConcept C78519656 @default.
• W4225793605 hasConceptScore W4225793605C126322002 @default.
• W4225793605 hasConceptScore W4225793605C127413603 @default.
• W4225793605 hasConceptScore W4225793605C141071460 @default.
• W4225793605 hasConceptScore W4225793605C146834321 @default.
• W4225793605 hasConceptScore W4225793605C162324750 @default.
• W4225793605 hasConceptScore W4225793605C164705383 @default.
• W4225793605 hasConceptScore W4225793605C168563851 @default.
• W4225793605 hasConceptScore W4225793605C2776893843 @default.
• W4225793605 hasConceptScore W4225793605C2777185221 @default.
• W4225793605 hasConceptScore W4225793605C2779695227 @default.
• W4225793605 hasConceptScore W4225793605C2779987240 @default.
• W4225793605 hasConceptScore W4225793605C2780645631 @default.
• W4225793605 hasConceptScore W4225793605C2780813298 @default.
• W4225793605 hasConceptScore W4225793605C34447519 @default.
• W4225793605 hasConceptScore W4225793605C71924100 @default.
• W4225793605 hasConceptScore W4225793605C78519656 @default.
• W4225793605 hasLocation W42257936051 @default.
• W4225793605 hasLocation W42257936052 @default.
• W4225793605 hasOpenAccess W4225793605 @default.
• W4225793605 hasPrimaryLocation W42257936051 @default.
• W4225793605 hasRelatedWork W1517714144 @default.
• W4225793605 hasRelatedWork W1948273063 @default.
• W4225793605 hasRelatedWork W2005906139 @default.
• W4225793605 hasRelatedWork W2094635878 @default.
• W4225793605 hasRelatedWork W2101686168 @default.
• W4225793605 hasRelatedWork W2122559033 @default.
• W4225793605 hasRelatedWork W2155054144 @default.
• W4225793605 hasRelatedWork W2396538349 @default.
• W4225793605 hasRelatedWork W2406786851 @default.
• W4225793605 hasRelatedWork W2799319321 @default.
• W4225793605 isParatext "false" @default.
• W4225793605 isRetracted "false" @default.
• W4225793605 workType "article" @default.